Cargando…

Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?

PURPOSE: Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence. MATERIALS AND METHODS: A total of 753 patients were diagnosed with loca...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Hyub, Son, Hee Seo, Cho, Seok, Kim, Sang Jin, Yoo, Dae Seon, Kang, Seok Ho, Park, Sung Yul, Park, Jinsung, Chang, Sung-Goo, Jeon, Seung Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506106/
https://www.ncbi.nlm.nih.gov/pubmed/25622589
http://dx.doi.org/10.4143/crt.2014.013
_version_ 1782381646799962112
author Lee, Sang Hyub
Son, Hee Seo
Cho, Seok
Kim, Sang Jin
Yoo, Dae Seon
Kang, Seok Ho
Park, Sung Yul
Park, Jinsung
Chang, Sung-Goo
Jeon, Seung Hyun
author_facet Lee, Sang Hyub
Son, Hee Seo
Cho, Seok
Kim, Sang Jin
Yoo, Dae Seon
Kang, Seok Ho
Park, Sung Yul
Park, Jinsung
Chang, Sung-Goo
Jeon, Seung Hyun
author_sort Lee, Sang Hyub
collection PubMed
description PURPOSE: Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence. MATERIALS AND METHODS: A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence. RESULTS: In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039). CONCLUSION: Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors.
format Online
Article
Text
id pubmed-4506106
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-45061062015-07-21 Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? Lee, Sang Hyub Son, Hee Seo Cho, Seok Kim, Sang Jin Yoo, Dae Seon Kang, Seok Ho Park, Sung Yul Park, Jinsung Chang, Sung-Goo Jeon, Seung Hyun Cancer Res Treat Original Article PURPOSE: Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence. MATERIALS AND METHODS: A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence. RESULTS: In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039). CONCLUSION: Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors. Korean Cancer Association 2015-07 2014-11-17 /pmc/articles/PMC4506106/ /pubmed/25622589 http://dx.doi.org/10.4143/crt.2014.013 Text en Copyright © 2015 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Sang Hyub
Son, Hee Seo
Cho, Seok
Kim, Sang Jin
Yoo, Dae Seon
Kang, Seok Ho
Park, Sung Yul
Park, Jinsung
Chang, Sung-Goo
Jeon, Seung Hyun
Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
title Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
title_full Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
title_fullStr Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
title_full_unstemmed Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
title_short Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
title_sort which patients should we follow up beyond 5 years after definitive therapy for localized renal cell carcinoma?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506106/
https://www.ncbi.nlm.nih.gov/pubmed/25622589
http://dx.doi.org/10.4143/crt.2014.013
work_keys_str_mv AT leesanghyub whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT sonheeseo whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT choseok whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT kimsangjin whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT yoodaeseon whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT kangseokho whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT parksungyul whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT parkjinsung whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT changsunggoo whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma
AT jeonseunghyun whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma